ClinicalTrials.gg
CompletedNCT06673927Updated Feb 10, 2025

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of YZJ-1139 in Healthy Participants

A Phase 1 interventional study of YZJ-1139 and YZJ-1139 in Insomnia, sponsored by Shanghai Haiyan Pharmaceutical Technology Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2025-02-10.

Sponsored by Shanghai Haiyan Pharmaceutical Technology Co., Ltd. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Registered 6 years 11 months after the study started (first participant enrolled Dec 2017, registered Nov 2024).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
104
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 198 studies in Sleep Initiation and Maintenance Disorders with a site in China — 82 open to participants now, 88 under way, 2 of them phase 3. Sleep Initiation and Maintenance Disorders · China.

Enrollment
73rd of 162
104 · median 88
Started
2017
with 8 others
Phase 1
13 of 198
1 open now
Registered
129th of 198
by date
Lead sponsor
9 of 198
Shanghai Haiyan Pharmaceutical Technology Co., Ltd.

Among the 198 studies in Sleep Initiation and Maintenance Disorders with a site in China, this one is the 73rd largest by enrollment of the 162 interventional ones that give a count, is one of 9 that started in 2017, is one of 13 in phase 1, and was the 129th registered.

Sleep Initiation and Maintenance Disorders

2,729 studies on the registry are indexed under Sleep Initiation and Maintenance Disorders; 731 are open to participants now.

Browse Sleep Initiation and Maintenance Disorders studies →

Open to participants now

82 of the 198 studies in Sleep Initiation and Maintenance Disorders with a site in China are open now. Recruiting first, the newest first:

77 more — sign in →

All 82 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 390 Sleep Initiation and Maintenance Disorders studies recruiting now, 153 (39%) set no upper age limit and 207 (53%) stop at 75 or younger; 59 take children under 18; 109 take healthy volunteers.

This study: 18 Years to 45 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 198 studies in Sleep Initiation and Maintenance Disorders with a site in China, or all of them as a file.
02

Study summary

Primary Objective:

  1. To evaluate the tolerability, safety of single and multiple doses of YZJ-1139 in healthy participants
  2. To evaluate the pharmacokinetic of single and multiple doses of YZJ-1139 in healthy participants

Secondary objectives:

To explore the safe tolerated dose of YZJ-1139, provide data support for the design of phase II dosing regimen

03

Conditions studied

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy subjects, with the proportion of a single gender in each group not less than 1/3;
  2. Aged between 18 and 45 years (inclusive of 18 and 45 years);
  3. The (BMI) ranges from 19 to 24 (inclusive of 19 and 24), where BMI = weight (kg) / height squared (m²). At the time of entering the study, the weight of female volunteers must be no less than 50 kg, and that of male volunteers must be no less than 55 kg;
  4. Those who pass comprehensive physical examinations (vital signs, height, weight, and chest and abdominal examinations, etc.) and laboratory tests (blood routine, blood biochemistry, urine routine, , infectious disease screening, etc.), and have no abnormalities or only minor abnormalities without clinical significance in 12-lead electrocardiogram, abdominal B-ultrasound (liver, gallbladder, pancreas, spleen, and kidneys), anteroposterior and lateral chest radiographs, etc.;
  5. Volunteers who can comprehend the procedures and methods of this study, are willing to strictly adhere to the clinical trial protocol to complete the trial, and sign the form.

Exclusion criteria

Exclusion Criteria:

  1. After researchers determine that the subject has a disease that affects drug absorption, distribution, metabolism, and excretion or may reduce compliance (cardiovascular, liver, kidney, gastrointestinal, immune, hematological, endocrine, metabolic, cancer, psychiatric and neurological conditions);
  2. A history of specific allergic reactions (such as asthma, eczema, allergic dermatitis); known allergies to the trial drug and its components; a history of drug allergies;
  3. A history of obstructive sleep apnea or ;
  4. A history of severe unconscious hypoglycemia;
  5. A history of stroke, chronic epilepsy, or neurological disorders;
  6. A history of diminished memory or abnormal behavior;
  7. A history of drug dependence within the past 2 years (smoking excluded), seizure disorders, syncope history;
  8. A illness within the past month before enrollment, especially severe infections, trauma, or major surgery;
  9. The use of any prescription drugs or herbal medicines within the past month before enrollment, and non-prescription drugs or food supplements within the past 2 weeks;
  10. Regular use of sedatives, sleeping pills, or other addictive drugs, and positive urine drug screening;
  11. had donated blood within the 3 months prior to the study, or had severe blood loss equivalent to at least 500 mL of blood loss;
  12. surface antigen positive, antibody positive, antibody positive, syphilis antibody positive;
  13. Patients who took enzyme inhibitors (itraconazole, erythromycin, boprevir, etc.), CYP3A enzyme inducers (rifampicin, carbamazepine) and/or CNS inhibitors (benzodiazepines, opioids, tricyclic antidepressants, etc.) 2 weeks before inclusion;
  14. Have a history of alcohol abuse (drinking 14 units of alcohol per week: 1 unit = 285 mL of beer, or 25 mL of spirits, or about 100 ml of wine) and test positive for alcohol;
  15. Smokers who smoked more than 5 or equivalent cigarettes per day in the 3 months before the test and those who tested positive for nicotine should not give up smoking during the test;
  16. Drinking excessive tea and coffee drinks (more than 8 cups) per day;
  17. Drinking alcohol, eating food and drink rich in xanthine or caffeine (including chocolate, tea, coffee, cola, etc.) or eating grapefruit, limes, etc., or food and drink prepared from them in the 3 days prior to inclusion;
  18. Participated in any clinical drug research or clinical trial of medical device within 3 months prior to screening;
  19. Pregnant and lactating women within 6 months from the subject's signature to the last administration of the study drug; Fertile women who do not use effective non-hormonal (Iuds, barrier contraception with spermicide or surgical sterilization, etc.) or are unwilling to continue using these methods; Fertile men are reluctant to use physical methods of contraception; Women who were menstruating during the trial (see annex 3 for details);
  20. There are any subjects that the investigator considers unsuitable for participation in this study.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
104 participants (actual)

Study arms

  • Experimental
    YZJ-1139 Single-dose Group

    Subjects will be randomized into two groups: the experimental group will receive YZJ-1139; the control group will receive placebo.

    Drug: YZJ-1139

  • Experimental
    YZJ-1139 multiple-dose Group

    Subjects will be randomized into two groups;the experimental group will receive YZJ-1139; the control group will receive placebo once a day, 7 days.

    Drug: YZJ-1139 · Drug: Placebo

Interventions

  • Single oral dose, 2mg, 5mg, 10mg, 20mg, 40mg, 60mg, 80mg

  • Multiple Dosing ,Each oral dose of 10 mg,20 mg,40 mg or 60 mg

  • DrugPlacebo

    Placebo administration

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

    Time frame: From Day 1 to Day 3 post single dose;From Day 1 to Day 14 post multiple dose;

Secondary outcomes

  1. Cmax of YZJ-1139

    Cmax is defined as the maximum concentration of drug.

    Time frame: From Day 1 to Day 2 post single dose;From Day 1 to Day 8 post multiple dose

  2. AUCinf of YZJ-1139

    AUCinf is defined as the concentration of drug extrapolated to infinite time.

    Time frame: From Day 1 to Day 2 post single dose;From Day 1 to Day 8 post multiple dose

  3. AUClast of YZJ-1139

    AUClast is defined as the concentration of drug from time zero to the last observable concentration.

    Time frame: From Day 1 to Day 2 post single dose;From Day 1 to Day 8 post multiple dose

  4. AUC0-τ of YZJ-1139

    AUC0-τ is defined as the area under the concentration-time curve over the dosing interval

    Time frame: From Day 1 to Day 8 post multiple dose

  5. Css,avg of YZJ-1139

    Css,avg is defined as the average steady state concentration

    Time frame: From Day 1 to Day 8 post multiple dose

  6. Css,min of YZJ-1139

    Css,min is defined as the minimum observed concentration at steady

    Time frame: From Day 1 to Day 8 post multiple dose

  7. Tmax of YZJ-1139

    Tmax is defined as the time (observed time point) of Cmax

    Time frame: From Day 1 to Day 2 post single dose;From Day 1 to Day 8 post multiple dose

  8. t1/2 of YZJ-1139

    Time frame: From Day 1 to Day 2 post single dose;From Day 1 to Day 8 post multiple dose

  9. CL/F of YZJ-1139

    CL/F is defined as the apparent oral clearance following administration of the drug

    Time frame: From Day 1 to Day 2 post single dose;From Day 1 to Day 8 post multiple dose

  10. Vz/F of YZJ-1139

    Vz/F is defined as the apparent volume of distribution of the drug

    Time frame: From Day 1 to Day 2 post single dose;From Day 1 to Day 8 post multiple dose

  11. Rac of YZJ-1139

    Rac is defined as the accumulation Ratio

    Time frame: From Day 1 to Day 8 post multiple dose

07

Study locations

1 site
  • Beijing Ditan Hospital Capital Medical University
    Beijing, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2017 to primary completion in Nov 2018, 11 months.

Of 23 industry-sponsored phase 1 interventional studies under Sleep Initiation and Maintenance Disorders, half reached primary completion within 4 months of starting (the median); a quarter within 1 and three quarters within 5. This study's 11 months is above that.

Counting every sponsor, half of 39 studies reached it within 5 months; a quarter within 3 and three quarters within 20.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 1, 2024
First posted
Nov 5, 2024
StartActual
Dec 1, 2017
Primary completionActual
Nov 21, 2018
CompletionActual
Mar 8, 2019
Last update
Feb 10, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 10, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06673927
Lead sponsor
Shanghai Haiyan Pharmaceutical Technology Co., Ltd.
Responsible party
Sponsor
First posted
Nov 5, 2024
Start date
Dec 1, 2017
Primary completion
Nov 21, 2018
Completion
Mar 8, 2019
Last update
Feb 10, 2025

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fazamorexant

Start the discussion